A Controlled Trial of Cyclosporine in the Treatment of Primary Biliary Cirrhosis

Authors:
  • JLJurgen Ludwig
    Jurgen Ludwig
  • KLKeith D. Lindor
    Keith D. Lindor
  • RJRoberta A. Jorgensen
    Roberta A. Jorgensen
  • WBWilliam P. Baldus
    William P. Baldus
  • HHHenry A. Homburger
    Henry A. Homburger
  • EDE. Rolland Dickson
    E. Rolland Dickson

Abstract
Primary biliary cirrhosis is a progressive disease of the liver characterized by the immunologic destruction of bile ducts; effective therapy is lacking. We therefore evaluated the safety and efficacy of low-dose cyclosporine in 29 patients with primary biliary cirrhosis without evidence of damage to the lobular architecture (precirrhotic disease) or portal hypertension. The patients were randomly assigned to receive either cyclosporine (4 mg per kilogram of body weight per day) or placebo.

This publication has 32 references indexed in Scilit: